Best Approaches to Switching Therapies for a Patient With Myelofibrosis

Reasons to switch JAK inhibitors include worsening blood counts and insufficient symptom or spleen response at maximum doses, with the goal of avoiding gaps in treatment by stopping one JAK inhibitor when ready to start the next to prevent symptom rebound while still allowing for potential increased efficacy from an alternative mechanism of action.

CML Alliance
Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart